To include your compound in the COVID-19 Resource Center, submit it here.

DBV's peanut allergy therapy misses in Phase III

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Viaskin Peanut (DBV-712) missed the primary endpoint in the Phase III PEPITES trial to treat peanut allergy in patients ages 4-11.

In

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE